HKMPY (Hikma Pharmaceuticals) Inventories, Work In Process: $137 Mil (As of Dec. 2025)


HKMPY Hikma Pharmaceuticals PLC HKMPY
87 GF Score
Price $41.23
GF Value $56.71
Valuation Modestly Undervalued
! 5 Warning Signs
View Full Analysis

What is Hikma Pharmaceuticals Inventories, Work In Process?

Hikma Pharmaceuticals HKMPY 87 Inventories, Work In Process is $137 Mil as of Dec. 2025. GuruFocus rates HKMPY with a GF Score™ of 87/100 and a GF Value™ of $56.71 (Modestly Undervalued). The stock has 5 warning signs investors should review.

Work in process is the part of a manufacturer's inventory that is in the production process and has not yet been completed and transferred to the finished goods inventory. Hikma Pharmaceuticals's work in process for the quarter that ended in Dec. 2025 was $137 Mil.

Hikma Pharmaceuticals Inventories, Work In Process Historical Data

* Premium members only.

The historical data trend for Hikma Pharmaceuticals's Inventories, Work In Process can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Hikma Pharmaceuticals Inventories, Work In Process Chart

Hikma Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Inventories, Work In Process
Get a 7-Day Free Trial Premium Member Only Premium Member Only 92.00 103.00 125.00 113.00 137.00

Hikma Pharmaceuticals Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Inventories, Work In Process Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 125.00 0.00 113.00 0.00 137.00
HKMPY
87GF Score
Hikma Pharmaceuticals PLC HKMPY
Inventories, Work In Process is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Hikma Pharmaceuticals Inventories, Work In Process Calculation

That part of a manufacturer's inventory that is in the production process and has not yet been completed and transferred to the finished goods inventory. This account contains the cost of the direct material, direct labor, and factory overhead placed into the products on the factory floor. A manufacturer must disclose in its financial statements the cost of its work-in-process as well as the cost of finished goods and materials on hand.

What does a Inventories, Work In Process of $137 Mil mean?
Hikma Pharmaceuticals (HKMPY) has a Inventories, Work In Process of $137 Mil as of Dec. 2025. Work in progress is the portion of inventory containing goods that are unfinished. View historical data on Hikma Pharmaceuticals and its competitors.
Is Hikma Pharmaceuticals' Inventories, Work In Process too high?
Hikma Pharmaceuticals' current Inventories, Work In Process is $137 Mil. Overall, Hikma Pharmaceuticals has a GF Score™ of 87/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Hikma Pharmaceuticals' Inventories, Work In Process compare to ZTS and UTHR?
Hikma Pharmaceuticals' Inventories, Work In Process of $137 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Inventories, Work In Process for a Drug Manufacturers company?
A good Inventories, Work In Process depends on the Drug Manufacturers industry context. However, Inventories, Work In Process should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Inventories, Work In Process mean?
A high Inventories, Work In Process can signal that a stock is expensive relative to its fundamentals. Work in progress is the portion of inventory containing goods that are unfinished. View historical data on Hikma Pharmaceuticals and its competitors. Hikma Pharmaceuticals's current Inventories, Work In Process is $137 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hikma Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Hikma Pharmaceuticals (HKMPY) is currently considered Modestly Undervalued. The stock's GF Value™ is $56.71, compared to a current price of $41.23 — trading 27.3% below its estimated fair value. The current Inventories, Work In Process is $137 Mil. Hikma Pharmaceuticals' overall GF Score™ is 87/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Inventories, Work In Process calculated?
Inventories, Work In Process is calculated from a company's financial statements. For Hikma Pharmaceuticals (HKMPY), the current Inventories, Work In Process is $137 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Hikma Pharmaceuticals (HKMPY) Overvalued in 2026?

Based on GuruFocus' analysis, Hikma Pharmaceuticals stock appears to be undervalued. The current stock price of $41.23 is trading 27.3% below its estimated GF Value™ of $56.71. GuruFocus considers Hikma Pharmaceuticals to be Modestly Undervalued.

Key valuation signals for HKMPY:

  • Inventories, Work In Process: $137 Mil
  • GF Value™: $56.71 vs. price of $41.23 (27.3% below fair value)
  • GF Score™: 87/100 with 5 warning signs

No single metric tells the full story. See the HKMPY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Hikma Pharmaceuticals Business Description

Address 10 Portman Square, London, GBR, W1H 6AZ
Hikma Pharmaceuticals PLC is engaged in developing, manufacturing, and marketing a broad range of generic, branded, and in-licensed pharmaceutical products. The firm operates in three segments: injectables, Rx, and branded. The majority of the company's revenue is generated from its injectables segment, which supplies hospitals across markets with generic injectable products, supported by its manufacturing facilities. Geographically, North America is the company's key revenue-generating market, followed by the Middle East and North Africa, the United Kingdom, Europe, and the rest of the world.
87GF Score

Get the complete analysis for HKMPY

Inventories, Work In Process is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$41.23
Price
$56.71
GF Value